Insider Selling: LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO Sells 68,906 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the completion of the transaction, the chief executive officer now directly owns 2,133,428 shares of the company’s stock, valued at approximately $161,500,499.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

LeMaitre Vascular Price Performance

LeMaitre Vascular stock opened at $76.00 on Friday. The stock has a market cap of $1.71 billion, a PE ratio of 50.33, a P/E/G ratio of 2.99 and a beta of 0.88. The stock’s fifty day moving average is $66.67 and its two-hundred day moving average is $59.46. LeMaitre Vascular, Inc. has a 1-year low of $44.27 and a 1-year high of $76.24.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05. The business had revenue of $53.48 million for the quarter, compared to analyst estimates of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The business’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.27 EPS. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Institutional Investors Weigh In On LeMaitre Vascular

Several hedge funds and other institutional investors have recently bought and sold shares of LMAT. Lindenwold Advisors INC acquired a new position in LeMaitre Vascular in the first quarter valued at $222,000. State Board of Administration of Florida Retirement System boosted its position in shares of LeMaitre Vascular by 12.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 29,258 shares of the medical instruments supplier’s stock valued at $1,942,000 after purchasing an additional 3,150 shares during the period. Sei Investments Co. boosted its position in shares of LeMaitre Vascular by 8.9% in the 1st quarter. Sei Investments Co. now owns 58,071 shares of the medical instruments supplier’s stock valued at $3,854,000 after purchasing an additional 4,731 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in LeMaitre Vascular during the 1st quarter worth approximately $352,000. Finally, Illinois Municipal Retirement Fund increased its position in LeMaitre Vascular by 3.0% during the first quarter. Illinois Municipal Retirement Fund now owns 11,690 shares of the medical instruments supplier’s stock worth $776,000 after buying an additional 335 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

LMAT has been the topic of a number of research reports. Stifel Nicolaus upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their target price for the stock from $59.00 to $75.00 in a report on Friday, April 26th. Barrington Research increased their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. KeyCorp started coverage on LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. JMP Securities increased their price target on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Finally, StockNews.com raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $73.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.